Physician profile
Ivan MD Robbins
NPI 1083713424
$8,319.21
in general payments reported to CMS, 2019-2025
9 companies · $4,591 in 2025
The $4,591 reported for 2025 was more than what 87% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $212 · 2020: $2,499 · 2021: $43.08 · 2023: $16.24 · 2024: $958 · 2025: $4,591.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,886 · Travel and Lodging: $1,517 · Food and Beverage: $146 · Education: $16.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,886.00 |
| Travel and Lodging | $1,516.55 |
| Food and Beverage | $146.32 |
| Education | $16.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $4,590.76 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $3,419.25 | 2020-2024 | |
| Actelion Pharmaceuticals US, INC. | $191.69 | 2019 | |
| Insmed, INC. | $64.96 | 2020-2023 | Arikayce |
| United Therapeutics Corporation | $30.44 | 2019-2021 | |
| Atricure, INC. | $22.11 | 2024 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ivan Robbins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.